Blomberg J, Vincic E, Jönsson C, Medstrand P, Pipkorn R
Department of Medical Microbiology, University of Lund, Sweden.
AIDS Res Hum Retroviruses. 1990 Dec;6(12):1363-72. doi: 10.1089/aid.1990.6.1363.
We analyzed nine sera from persons unlikely to be HIV infected which had an IgG reactivity directed against HIV-1 p24, and in two cases also to its precursor p55, but to no other HIV proteins, nor to proteins of the H9 host cell, in electrophoretic immunoblots (EIB). These sera are also referred to as having an indeterminate HIV EIB pattern or as HIV antibody false positive sera. Seven of nine sera reacted with longer (61-77 amino acids) and none with shorter (17-25 amino acids) p24-derived peptides in enzyme immunoassays (EIAs). This is compatible with a conformational (discontinuous) nature of the epitopes involved in many false positive HIV-1 p24 antibody reactions. Four sera reacted with an N-terminal, one with an internal, and two with a C-terminal fragment. Each of the seven sera thus only reacted with one of the long p24 peptides. The specificity and singularity of the reaction was further demonstrated by competition and/or absorption experiments with synthetic peptides. In contrast, 18 of 20 confirmed HIV-1+ sera with p24 reactivity in EIB reacted with at least one and often several of the longer peptides, most frequently the C-terminal one. Thus, the distribution of peptide reactivity of true HIV-1 antibody-positive sera was different from that of the falsely reactive sera. According to two of several explanations, these antibodies may have arisen because of (1) molecular mimicry by chance or by functional selection, (2) immunization by activation, noninfectious exposure, or infection involving non-HIV endogenous or exogenous retroviral antigens. The latter gains some support from our finding of antibody reactions with capsid proteins of the simian viruses, simian sarcoma-associated virus (SSAV), and Mason-Pfizer monkey retrovirus in some of the p24 +/- p55 reactive sera.
我们分析了9份来自不太可能感染HIV的人的血清,这些血清在电泳免疫印迹(EIB)中具有针对HIV-1 p24的IgG反应性,其中2份血清还对其前体p55有反应,但对其他HIV蛋白以及H9宿主细胞的蛋白均无反应。这些血清也被称为具有不确定的HIV EIB模式或HIV抗体假阳性血清。在酶免疫测定(EIA)中,9份血清中有7份与较长的(61 - 77个氨基酸)p24衍生肽发生反应,而与较短的(17 - 25个氨基酸)p24衍生肽均无反应。这与许多HIV-1 p24抗体假阳性反应中所涉及的表位的构象(不连续)性质相符。4份血清与N端片段反应,1份与内部片段反应,2份与C端片段反应。因此,这7份血清中的每一份仅与一种长p24肽发生反应。通过与合成肽的竞争和/或吸收实验进一步证明了反应的特异性和独特性。相比之下,在EIB中具有p24反应性的20份经确认的HIV-1阳性血清中有18份与至少一种且通常是几种较长的肽发生反应,最常见的是C端肽。因此,真正的HIV-1抗体阳性血清的肽反应性分布与假反应性血清不同。根据几种解释中的两种,这些抗体可能是由于(1)偶然或通过功能选择的分子模拟,(2)通过激活、非感染性暴露或涉及非HIV内源性或外源性逆转录病毒抗原的感染而产生的免疫反应。我们在一些p24 +/- p55反应性血清中发现与猿猴病毒、猿猴肉瘤相关病毒(SSAV)和梅森 - Pfizer猴逆转录病毒的衣壳蛋白发生抗体反应,这一发现为后者提供了一些支持。